The Effect of Facial Effleurage on Acute Rhinosinusitis
Status
Conditions
Treatments
Details and patient eligibility
About
Rhinosinusitis accounts for 12% of the total antibiotic prescriptions filled in the United States annually; however, the majority of rhinosinusitis cases have been proposed to have a viral etiology, or are capable of spontaneously resolving. This overuse of antibiotics is contributing to the development of antibiotic-resistant human pathogenic bacteria, and increasing patient mortality to previously easily cured diseases. This is also causing an unnecessary financial burden especially for uninsured, rural families. Facial Effleurage (FE) is an osteopathic manipulative therapy that allows physicians an alternative therapy to prescribing antibiotics; however, the only scientific literature on the technique is weak in design and execution. This will be a randomized, placebo-controlled clinical trial to test the ability of FE to reduce symptom severity over time, reduce the cellular infiltrate into the nasal cavity, and to more quickly resolve the symptoms of rhinosinusitis compared to antibiotic treatment. This methodical approach to the efficacy of FE has the potential to impact the treatment recommendations of physicians immediately, and to convince more physicians to prescribe less antibiotics and rely more heavily on FE.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Presents with no acute disease OR
- Presents with anterior/posterior mucopurulent drainage and nasal obstruction/facial pain/pressure/fullness
- Independently and without coercion read, understood, and signed the informed consent form
- Is between 18-69 years old.
Exclusion criteria
- History of: cancer, HIV, HIV exposure, osteoporosis, acute hepatitis, cystic fibrosis, type-1 diabetes, taking insulin for diabetes, deep vein thrombosis, pulmonary embolism
- History of recent trauma to the liver or spleen or surgery within the past 6 months
- Currently pregnant or nursing
- Have a comorbidity that requires antibiotics or antiviral therapy
- Have a fever greater than 102.5F
- Used topical antimicrobials in the past 30 days
- Taken oral antimicrobials in the past 15 days
- Participated in a clinical trial in the past 6 months
- Have current face or neck bone fractures
- Have abscesses, incisions, or nasal polyps visible on physical examination
- Need to be hospitalized for any reason
Trial design
Primary purpose
Allocation
Interventional model
Masking
138 participants in 7 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal